BioSpace News Archive

Drug Development

Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis

Oculis Holding AG announced the completion of enrollment in its multi-center, randomized, double-blind, placebo-controlled Phase 2 ACUITY trial evaluating the safety and tolerability of OCS-05 in patients with Acute Optic Neuritis.

May 8, 2024
·
7 min read
Biotech Bay

89bio to Participate in the BofA Securities 2024 Health Care Conference

89bio, Inc. announced that the Company’s Management will present at the BofA Securites 2024 Health Care Conference on Wednesday, May 15, 2024 at 2:20 PM PDT and participate in one-on-one investor meetings.

May 8, 2024
·
1 min read
Business

Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones

Design Therapeutics, Inc., a biotechnology company developing treatments for serious degenerative genetic diseases, announced first quarter 2024 financial results along with recent business highlights and upcoming milestones.

May 8, 2024
·
9 min read
U.S. Oncology Molecular Diagnostics Market Size to Reach USD 2.74 Bn by 2033

According to recent study by nova one advisor, the U.S. oncology molecular diagnostics market size was valued at USD 0.85 billion in 2023 and is anticipated to reach around USD 2.74 billion by 2033, growing at a CAGR of 12.41% from 2024 to 2033

May 8, 2024
·
12 min read
Business

Erasca Reports First Quarter 2024 Business Updates and Financial Results

Erasca, Inc. provided business updates and reported financial results for the fiscal quarter ended March 31, 2024.

May 8, 2024
·
10 min read
Press Releases

Maravai LifeSciences Reports First Quarter 2024 Financial Results

Maravai LifeSciences Holdings, Inc., a global provider of life science reagents and services to researchers and biotech innovators, reported financial results for the first quarter ended March 31, 2024, together with other business updates.

May 8, 2024
·
19 min read
Business

Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

Olema Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

May 8, 2024
·
11 min read
Business

Terns Pharmaceuticals Announces Leadership Changes

Terns Pharmaceuticals, Inc. announced the appointment of Scott Harris as chief development officer effective May 28, 2024 and the upcoming departure of Erin Quirk, M.D., president, head of research and development.

May 8, 2024
·
6 min read
Business

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Relmada Therapeutics, Inc., a late-stage biotechnology company addressing diseases of the central nervous system, provided a corporate update and announced preliminary and unaudited financial results for the first quarter ended March 31, 2024.

May 8, 2024
·
10 min read
Business

Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress

Arcturus Therapeutics Holdings Inc., a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, announced its financial results for the first quarter ended March 31, 2024, and provided corporate updates.

May 8, 2024
·
13 min read